Updated:
Cure Ventures
Cure Ventures is a life sciences venture capital firm focusing on investing in de novo company formation around groundbreaking curative technologies.
Overview
Cure Ventures is a life sciences venture capital firm focusing on investing in de novo company formation around groundbreaking curative technologies. The firm’s investment strategy is founded on three tenets: a seed funding model that allows Cure to de-risk the science and set companies up for success; genetic validation that increases the probability of success; and embedded Cure operators to drive day-to-day decision making with founders. With entrepreneurs, the firm aims to bring cures to life and save lives by funding and working alongside entrepreneurs developing therapeutics that cure life-altering diseases.
General information
Firm type
Venture Capital
Year founded
2021
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, United States
Principals
David Fallace
J.D. / M.B.A. — Managing Partner and Co-Founder
Richard J. Lim
M.B.A. — Managing Partner
William Amsbaugh
M.S. — CTO and Partner
Drew King
CPA / M.S.A. — CFO and Partner
Jeno Gyuris
Ph.D. — Partner
May Han
Ph.D. — Partner
Jeffrey M. Jonas
MD — Partner
Milenko Cicmil
Ph.D. — Venture Partner
Kayarash Karimian
Ph.D. — Senior Associate
Virginia Lyle King
Ph.D. — Senior Associate
Weihan Liu
Ph.D. — Associate
Albert J. Robichaud
Ph.D. — Partner
Sophie Robinson
Ph.D. — Senior Associate
Sector focus
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: